Hanane Chaibainou
Acute Care · Westampton, NJNPI 1316241565
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $10,668 of the $16,178 with a category attached, or 65.9%. Insightec,inc accounts for 67.3% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $13,718, more than ten times the $338 reported in 2021. Among acute care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $63.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insightec,inc$11K
- AbbVie$1K
- UCB, Inc.$680
- Teva Pharmaceuticals USA, Inc.$482
- Lundbeck LLC$302
- Pfizer$297
- plus $2K from 26 others
What the payments were for
- Travel & lodging$10,66866%
- Food & beverage$5,51034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insightec,inc | 10 | $10,889 |
| AbbVie | 85 | $1,352 |
| UCB, Inc. | 20 | $680 |
| Teva Pharmaceuticals USA, Inc. | 18 | $482 |
| Lundbeck LLC | 13 | $302 |
| Pfizer | 13 | $297 |
| E.r. Squibb & Sons, L.L.C. | 2 | $250 |
| Medtronic | 9 | $214 |
| Axsome Therapeutics, Inc. | 7 | $201 |
| Lilly USA, LLC | 6 | $189 |
| Biogen | 7 | $173 |
| Neurocrine Biosciences, Inc. | 9 | $163 |
| Eisai Inc. | 10 | $161 |
| Bristol Myers Squibb | 10 | $152 |
| Scilex Pharmaceuticals Inc. | 8 | $128 |
| Boston Scientific | 4 | $110 |
| Argenx US, Inc. | 4 | $72 |
| Grifols USA, LLC | 3 | $55 |
| MDD US Operations, LLC | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Impel Pharmaceuticals LLC | 1 | $18 |
| Harmony Biosciences LLC | 1 | $17 |
| SK Life Science, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Aucta Pharmaceuticals, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,178 in reported general payments places this provider in the 95th percentile of 656 acute care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 24 | $38,647 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,641 |
| Memantine Hcl | 205 | $7,753 |
| Rasagiline Mesylate | 18 | $5,947 |
| Lacosamide | 26 | $5,199 |
| Gabapentin | 114 | $2,361 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 63 | $2,167 |
| Divalproex Sodium | 15 | $2,079 |
| Topiramate | 26 | $1,937 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $1,876 |
| Donepezil Hcl | 96 | $1,299 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 11 | $1,074 |
| Levetiracetam | 30 | $1,028 |
| Primidone | 26 | $935 |
| Lamotrigine | 17 | $851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $1,352 | $38,64724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 656 acute care providers in New Jersey.
Other acute care in Westampton
- Gabriella MagarelliHackensack$44K
- Per RosenkvistLivingston$29K
- Matthew OstroffPaterson$27K
- Ellen McCueNeptune$26K
- Suzanne ShuggLivingston$25K
- Maria Tedi CoronelHackensack$19K
- Jennifer McCarthyNewark$16K
- Jennifer HarrarCamden$16K
- Vincent FroncekFlemington$14K
- Linda SuplickiMorristown$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.